Susceptibility vessel sign predicts poor clinical outcome for acute stroke patients untreated by thrombolysis

Liu,Huiqin; Mei,Wenli; Huang,Yue; Li,Yongli; Chen,Zuzhi; Li,Dongdong; Ye,Hong; Zhang,Jiewen

doi:10.3892/etm.2017.5195

Susceptibility vessel sign predicts poor clinical outcome for acute stroke patients untreated by thrombolysis

Authors:
- Huiqin Liu
- Wenli Mei
- Yue Huang
- Yongli Li
- Zuzhi Chen
- Dongdong Li
- Hong Ye
- Jiewen Zhang
View Affiliations

Affiliations: Department of Neurology, People's Hospital of Zhengzhou University, Zhengzhou, Henan 450003, P.R. China, Department of Radiology, People's Hospital of Zhengzhou University, Zhengzhou, Henan 450003, P.R. China, Department of Neurology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453100, P.R. China
Published online on: September 22, 2017 https://doi.org/10.3892/etm.2017.5195
Pages: 5207-5213

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The location and length of the susceptibility vessel sign (SVS) predicts poor outcome for patients having received reperfusion therapy. The aim of the present study was to assess the predictive value of SVS regarding the clinical outcome for patients untreated with thrombolysis. A retrospective study on acute stroke patients who underwent multimodal magnetic resonance imaging within 3 days from the onset of symptoms was performed. None of the patients had received thrombolysis therapy. The presence, location and length of the SVS were assessed. Uni‑ and multivariate analyses were used to examine the association between SVS and clinical outcome. A total of 43 SVS+ and 73 SVS‑ patients were included in the study. A modified Rankin Scale (mRS) of ≤2 at 3 months was determined in 41.9% of patients in the SVS+ group and 79.4% in the SVS‑ group (P<0.001). Multivariate analysis revealed that the presence of SVS was an independent parameter to predict mRS >2 at 3 months (odds ratio, 3.390; 95% confidence interval, 1.122‑10.240; P=0.030). For patients with SVS+ status, the location and length of the SVS were not independent predictors of the clinical outcome. In conclusion, the presence of SVS may predict poor clinical outcome for acute stroke patients untreated with thrombolysis.

View Figures

View References

1	Somford DM, Nederkoorn PJ, Rutgers DR, Kappelle LJ, Mali WP and van der Grond J: Proximal and distal hyperattenuating middle cerebral artery signs at CT: Different prognostic implications. Radiology. 223:667–671. 2002. View Article : Google Scholar : PubMed/NCBI
2	Schellinger PD, Chalela JA, Kang DW, Latour LL and Warach S: Diagnostic and prognostic value of early MR Imaging vessel signs in hyperacute stroke patients imaged <3 h and treated with recombinant tissue plasminogen activator. AJNR Am J Neuroradiol. 26:618–624. 2005.PubMed/NCBI
3	Flacke S, Urbach H, Keller E, Träber F, Hartmann A, Textor J, Gieseke J, Block W, Folkers PJ and Schild HH: Middle cerebral artery (MCA) susceptibility sign at susceptibility-based perfusion MR imaging: Clinical importance and comparison with hyperdense MCA sign at CT. Radiology. 215:476–482. 2000. View Article : Google Scholar : PubMed/NCBI
4	Cho KH, Kim JS, Kwon SU, Cho AH and Kang DW: Significance of susceptibility vessel sign on T2*-weighted gradient echo imaging for identification of stroke subtypes. Stroke. 36:2379–2383. 2005. View Article : Google Scholar : PubMed/NCBI
5	Park MG, Yoon CH, Baik SK and Park KP: Susceptibility vessel sign for intra-arterial thrombus in acute posterior cerebral artery infarction. J Stroke Cerebrovasc Dis. 24:1229–1234. 2015. View Article : Google Scholar : PubMed/NCBI
6	Kimura K, Iguchi Y, Shibazaki K, Watanabe M, Iwanaga T and Aoki J: M1 susceptibility vessel sign on T2* as a strong predictor for no early recanalization after IV-t-PA in acute ischemic stroke. Stroke. 40:3130–3132. 2009. View Article : Google Scholar : PubMed/NCBI
7	Aoki J, Kimura K, Shibazaki K, Saji N, Uemura J, Sakamoto Y and Nagai K: The susceptibility vessel sign at the proximal M1: A strong predictor for poor outcome after intravenous thrombolysis. J Neurol Sci. 348:195–200. 2015. View Article : Google Scholar : PubMed/NCBI
8	Aoki J, Kimura K, Shibazaki K, Sakamoto Y, Saji N and Uemura J: Location of the susceptibility vessel sign on T2*-weighted MRI and early recanalization within 1 hour after tissue plasminogen activator administration. Cerebrovasc Dis Extra. 3:111–120. 2013. View Article : Google Scholar : PubMed/NCBI
9	Aoki J, Kimura K, Shibazaki K, Saji N, Uemura J, Sakamoto Y and Nagai K: The susceptibility vessel sign at the proximal M1: A strong predictor for poor outcome after intravenous thrombolysis. J Neurol Sci. 348:195–200. 2015. View Article : Google Scholar : PubMed/NCBI
10	Legrand L, Naggara O, Turc G, Mellerio C, Roca P, Calvet D, Labeyrie MA, Baron JC, Mas JL, Meder JF, et al: Clot burden score on admission T2*-MRI predicts recanalization in acute stroke. Stroke. 44:1878–1884. 2013. View Article : Google Scholar : PubMed/NCBI
11	Yan S, Hu H, Shi Z, Zhang X, Zhang S, Liebeskind DS and Lou M: Morphology of susceptibility vessel sign predicts middle cerebral artery recanalization after intravenous thrombolysis. Stroke. 45:2795–2797. 2014. View Article : Google Scholar : PubMed/NCBI
12	Soize S, Batista AL, Regent C Rodriguez, Trystram D, Tisserand M, Turc G, Serre I, Ben Hassen W, Zuber M, Calvet D, et al: Susceptibility vessel sign on T2* magnetic resonance imaging and recanalization results of mechanical thrombectomy with stent retrievers: A multicentre cohort study. Eur J Neurol. 22:967–972. 2015. View Article : Google Scholar : PubMed/NCBI
13	Yan S, Hu H, Shi Z, Zhang X, Zhang S, Liebeskind DS and Lou M: Morphology of susceptibility vessel sign predicts middle cerebral artery recanalization after intravenous thrombolysis. Stroke. 45:2795–2797. 2014. View Article : Google Scholar : PubMed/NCBI
14	Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL and Marsh EE III: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke. 24:35–41. 1993. View Article : Google Scholar : PubMed/NCBI
15	Naggara O, Raymond J, Ayllon M Domingo, Al-Shareef F, Touzé E, Chenoufi M, Gerber S, Mellerio C, Zuber M, Meder JF, et al: T2* ‘susceptibility vessel sign’ demonstrates clot location and length in acute ischemic stroke. PLoS One. 8:e767272013. View Article : Google Scholar : PubMed/NCBI
16	Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, et al: Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic. stroke. 34:e109–e137. 2003. View Article : Google Scholar : PubMed/NCBI
17	Apoil M, Turc G, Tisserand M, Calvet D, Naggara O, Domigo V, Baron JC, Oppenheim C and Touzé E: Clinical and magnetic resonance imaging predictors of very early neurological response to intravenous thrombolysis in patients with middle cerebral artery occlusion. J Am Heart Assoc. 2:e0005112013. View Article : Google Scholar : PubMed/NCBI